Latham & Watkins Advises Manifold Bio on US$2 Billion Strategic Collaboration With Roche to Develop Multiple Next-Generation Brain Shuttles for Neurological Diseases

Manifold Bio, a platform therapeutics company pioneering AI-guided drug discovery coupled with direct-to-vivo measurement, has announced a strategic research collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY). The partnership will apply Manifold's proprietary tissue-targeting shuttle portfolio and mDesign AI-driven in vivo discovery engine to create multiple next-generation BBB shuttles for the treatment of neurological and neurodegenerative diseases.

Latham & Watkins advised Manifold Bio in the transaction with a corporate team led by Bay Area partner Kate Hillier, with associate Arun Mohan. Advice was also provided on arbitration matters by New York partner John Pierce; and on tax matters by Bay Area partner Grace Lee, with associate Derek Gumm.